Brentuximab vedotin: Its role in the treatment of anaplastic large cell and hodgkin's lymphoma

Drugs of Today

Volumn 48, Issue 4, 2012, Pages 259-270

  Haddley, K ^a  

^a NONE

Author keywords

Antibody drug conjugates; Brentuximab vedotin; CD30 antigen; Hodgkin's lymphoma anaplastic large cell lymphoma

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IRATUMUMAB; KETOCONAZOLE; MIDAZOLAM; PREDNISONE; PROCARBAZINE; RIFAMPICIN; RITUXIMAB; VINCRISTINE;

ANAPHYLACTIC SHOCK; ANEMIA; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONNECTIVE TISSUE DISEASE; DEEP VEIN THROMBOSIS; DIABETIC COMA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL PAIN; HEART DISEASE; HEMOPTYSIS; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; IC 50; IMMUNOPHENOTYPING; IN VITRO SELECTION; IN VIVO STUDY; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LUNG EMBOLISM; LUNG TOXICITY; MENTAL DISEASE; METABOLIC DISORDER; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEURALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMOTHORAX; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RESPIRATORY FAILURE; RETINA VEIN OCCLUSION; REVIEW; SALVAGE THERAPY; SEPSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NEOADJUVANT THERAPY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84860736736     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.4.1788435     Document Type: Review

References (88)

1. Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W., Tubiana, M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971, 31(11): 1860-1.
2. Lister, T.A., Crowther, D., Sutcliffe, S.B. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989, 7(11): 1630-6. (Pubitemid 19272832)
3. Hodgkin On some Morbid Appearances of the Absorbent Glands and Spleen. Med Chir Trans 1832, 17: 68-114.
4. Reed, D. On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 1902, 10: 133-9.
5. Connors, J.M. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005, 23(26): 6400-8. (Pubitemid 46222240)
6. Canellos, G.P., Anderson, J.R., Propert, K.J. et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327(21): 1478-84.
7. Gualberto, A. Brentuximab vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 2012, 21(2): 205-16.
8. Janik, J.E., Morris, J.C., Pittaluga, S. et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 2004, 104(10): 3355-7. (Pubitemid 39507157)
9. Tilly, H., Gaulard, P., Lepage, E. et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997, 90(9): 3727-34. (Pubitemid 27473445)
10. Savage, K.J. Prognosis and primary therapy in peripheral Tcell lymphomas. Hematology Am Soc Hematol Educ Program 2008: 280-8.
11. Savage, K.J., Harris, N.L., Vose, J.M. et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111(12): 5496-504.
12. Schwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H., Schaadt, M., Diehl, V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299(5878): 65-7. (Pubitemid 12049770)
13. Durkop, H., Foss, H.D., Eitelbach, F., Anagnostopoulos, I., Latza, U., Pileri, S., Stein, H. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol 2000, 190(5): 613-8. (Pubitemid 30164492)
14. Younes, A., Kadin, M.E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003, 21(18): 3526-34. (Pubitemid 46594087)
15. Tzankov, A., Zimpfer, A., Pehrs, A.C. et al. Expression of Bcell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003, 16(11): 1141-7. (Pubitemid 37414209)
16. Tzankov, A., Krugmann, J., Fend, F., Fischhofer, M., Greil, R., Dirnhofer, S. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res 2003, 9(4): 1381-6. (Pubitemid 36418390)
17. Smith, C.A., Gruss, H.J., Davis, T. et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73(7): 1349-60. (Pubitemid 23201148)
18. Younes, A., Carbone, A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999, 14(3): 135-43. (Pubitemid 29495742)
19. Younes, A. CD30-targeted antibody therapy. Curr Opin Oncol 2011, 23(6): 587-93.
20. Hirsch, B., Hummel, M., Bentink, S. et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008, 172(2): 510-20. (Pubitemid 351282036)
21. Mir, S.S., Richter, B.W., Duckett, C.S. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000, 96(13): 4307-12.
22. Oflazoglu, E., Kennedy, D., Sievers, E.L. et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin's lymphoma. Ann Oncol [10th Int Conf Malig Lymphoma (June 4-7, Lugano) 2008] 2008, 19(Suppl. 4): Abst 529.
23. Oflazoglu, E., Kissler, K.M., Sievers, E.L., Grewal, I.S., Gerber, H.P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008, 142(1): 69-73. (Pubitemid 351783148)
24. Meyer, R.M., Gospodarowicz, M.K., Connors, J.M. et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited- stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23(21): 4634-42. (Pubitemid 46237440)
25. Horning, S., Fanale, M., deVos, S. et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol [10th Int Conf Malig Lymphoma (June 4-7, Lugano) 2008] 2008, 19(Suppl. 4): 120-1.
26. Byrne, B.J., Gockerman, J.P. Salvage therapy in Hodgkin's lymphoma. Oncologist 2007, 12(2): 156-67.
27. Brugieres, L., Pacquement, H., Le Deley, M.C. et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 2009, 27(30): 5056-61.
28. Andersson, P.O., Braide, I., Nilsson-Ehle, H. Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy. Leuk Lymphoma 2002, 43(12): 2351-3. (Pubitemid 35386158)
29. Gambacorti-Passerini, C., Messa, C., Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011, 364(8): 775-6.
30. Zamkoff, K.W., Matulis, M.D., Mehta, A.C., Beaty, M.W., Hutchison, R.E., Gentile, T.C. High-dose therapy and autologous stem cell transplant does not result in long-term disease- free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004, 33(6): 635-8. (Pubitemid 38455926)
31. King, K.M., Younes, A. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2001, 1(2): 177-86. (Pubitemid 34679409)
32. Falini, B., Flenghi, L., Fedeli, L. et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 1992, 82(1): 38-45.
33. Bartlett, N.L., Younes, A., Carabasi, M.H. et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111(4): 1848-54. (Pubitemid 351451492)
34. Wahl, A.F., Klussman, K., Thompson, J.D. et al. The anti- CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002, 62(13): 3736-42. (Pubitemid 34728855)
35. Ansell, S.M., Horwitz, S.M., Engert, A. et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25(19): 2764-9. (Pubitemid 47123185)
36. Ricart, A.D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011, 17(20): 6417-27.
37. Alley, S.C., Okeley, N.M., Senter, P.D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010, 14(4): 529-37.
38. Francisco, J.A., Cerveny, C.G., Meyer, D.L., Siegall, C., Senter, P.D., Wahl, A.F. SGN-35, an anti-CD30 antibody-drug conjugate with potent antitumor activity. Proc Am Assoc Cancer Res [94th Annu Meet Am Assoc Cancer Res (AACR) (July 10-14, Washington, D.C.) 2003] 2003, 44(2nd Ed.): Abst R770.
39. Francisco, J.A., Cerveny, C.G., Meyer, D.L. et al. cAC10- vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102(4): 1458-65. (Pubitemid 36988057)
40. Senter, P., Doronina, S., Toki, B. et al. Potent monoclonal antibody drug conjugates: The role of linker stability in efficacy, toxicity, and specificity. Proc Am Assoc Cancer Res [94th Annu Meet Am Assoc Cancer Res (AACR) (July 10-14, Washington, D.C.) 2003] 2003, 44(2nd Ed.): Abst 6425.
41. Doronina, S.O., Toki, B.E., Torgov, M.Y. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21(7): 778-84. (Pubitemid 36791396)
42. Okeley, N.M., Miyamoto, J.B., Zhang, X. et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010, 16(3): 888-97.
43. Katz, J., Janik, J.E., Younes, A. Brentuximab Vedotin (SGN-35). Clin Cancer Res 2011, 17(20): 6428-36.
44. Okeley, N.M., Alley, S.C., Cerveny, C.G. et al. Specific tumor targeting and potent bystander killing with SGN-35, an anti-CD30 antibody drug conjugate. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 231.
45. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L., Forero-Torres, A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363(19): 1812-21.
46. Hamblett, K.J., Barton, J., Cerveny, C.G. et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30(+) malignancies. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13 Atlanta) 2005] 2005, 106(11): Abst 610.
47. Hamblett, K.J., Meyer, D.L., Chace, D.F. et al. Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate. Proc Am Assoc Cancer Res [95th Annu Meet Am Assoc Cancer Res (AACR) (March 27-31, Orlando) 2004] 2004, 45: Abst 624.
48. Hamblett, K.J., Senter, P.D., Chace, D.F. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10(20): 7063-70. (Pubitemid 39383058)
49. Sanderson, R.J., Hering, M.A., James, S.F. et al. In vivo druglinker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005, 11(2 Pt 1): 843-52. (Pubitemid 40116913)
50. Alley, S.C., Kissler, K., Morris-Tilden, C., Miyamoto, J., Senter, P.D., Benjamin, D.R. Effective tumor targeting by auristatin antibody-drug conjugates. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 4088.
51. Phase I open-label dose finding study for CD30 positive hematologic malignancies (NCT00430846). ClinicalTrials.gov Web site, Accessed February 23, 2012.
52. Younes, A., Forero-Torres, A., Bartlett, N. et al. A novel antibody- drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: Preliminary results of a phase I tolerability study. Haematologica [7th Int Symp Hodgkin Lymphoma (Nov 3-7, Cologne) 2007] 2007, 92(Suppl. 5): Abst P099bis.
53. Younes, A., Forero-Torres, A., Bartlett, N.L., Leonard, J.P., Lynch, C., Kennedy, D.A., Sievers, E. Multiple complete responses in a phase I dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1006.
54. Younes, A., Forero-Torres, A., Bartlett, N.L. et al. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. Ann Oncol [10th Int Conf Malig Lymphoma (June 4-7, Lugano) 2008] 2008, 19(Suppl. 4): Abst 141.
55. Younes, A., Forero-Torres, A., Bartlett, N.L. et al. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 8526.
56. Younes, A., Forero-Torres, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Sievers, E.L. Robust antitumor activity of the antibody-drug conjugate SGN-35 when administered every 3 weeks to patients with relapsed or refractory CD30 positive hematologic malignancies in a phase 1 study. Haematologica [14th Congr Eur Hematol Assoc (EHA) (June 4-7, Berlin) 2009] 2009, 94: Abst 0503.
57. Bartlett, N., Forero-Torres, A., Rosenblatt, J. et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 8500.
58. Fanale, M., Bartlett, N.L., Forero-Torres, A. et al. The antibody- drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. Blood [51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 2731.
59. Fanale, M.A., Forero-Torres, A., Rosenblatt, J.D. et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012, 18(1): 248-55.
60. Fanale, M., Franklin, A., Radhakrishnan, R. et al. Complete remissions observed in a subset of pediatric patients with CD30-expressing malignant lymphomas treated in clinical studies of brentuximab vedotin (SGN-35). Eur J Cancer 2011, 47(Suppl. 1): Abst 9201.
61. Bartlett, N., Grove, L.E., Kennedy, D.A., Sievers, E.L., Forero- Torres, A. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. 46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010, Abst 8062.
62. Advani, R., Forero-Torres, A., Fanale, M. et al. Objective responses with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) who refused or were ineligible for Autologous Stem Cell Transplantation (ASCT). 16th Congr Eur Hematol Assoc (EHA) (June 9-12, London) 2011, Abst 0518.
63. Phase I open-label dose finding study of SGN-35 for CD30 positive hematologic malignancies (NCT00430846). ClinicalTrials.gov Web site, Accessed February 23, 2012.
64. A phase I dose escalation study of SGN-35 alone and in combination with gemcitabine for CD30-positive malignancies (NCT00649584). ClinicalTrials.gov Web site, Accessed February 23, 2012.
65. Clinical pharmacology study of brentuximab vedotin (SGN- 35) (NCT01026415). ClinicalTrials.gov Web site, Accessed February 23, 2012.
66. A phase 1 study of brentuximab vedotin combined with multi-agent chemotherapy for Hodgkin lymphoma (NCT01060904). ClinicalTrials.gov Web site, Accessed February 23, 2012.
67. A phase 1 study of brentuximab vedotin given sequentially and combined with multi-agent chemotherapy for CD30- positive mature T-cell and NK-cell neoplasms (NCT01309789). ClinicalTrials.gov Web site, Accessed February 23, 2012.
68. Phase I sequential & concurrent brentuximab vedotin +CHOP in systemic anaplastic large cell lymphoma. http://med.stanford.edu/clinicaltrials/detail. do?studyId=7485. Accessed March 4, 2012.
69. Study of brentuximab vedotin (SGN-35) in pediatric patients with relapsed or refractory systemic anaplastic large-cell lymphoma or Hodgkin lymphoma (NCT01492088). ClinicalTrials.gov Web site, Accessed February 23, 2012.
70. Fromm, J.R., McEarchern, J.A., Kennedy, D., Anju, T., Shustov, A.R., Gopal, A.K. Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab vedotin (SGN-35): Novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin lymphoma. Blood [52nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 1789.
71. Cardiac safety study of brentuximab vedotin (SGN-35) (NCT01026233). ClinicalTrials.gov Web site, Accessed March 4, 2012.
72. Chen, R., Gopal, A.K., Smith, S.E. et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN 35) in patients with relapsed or refractory Hodgkin lymphoma Blood [52nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 283.
73. Chen, R.W., Gopal, A.K., Smith, S.E. et al. SGN-35, an anti- CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30(+) malignancies. 47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011, Abst 8031.
74. A pivotal open-label trial of brentuximab vedotin for Hodgkin lymphoma (NCT00848926). ClinicalTrials.gov Web site, Accessed February 23, 2012.
75. Shustov, A.R., Advani, R., Brice, P. et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood [52nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 961.
76. A phase 2 open label trial of brentuximab vedotin (SGN-35) for systemic anaplastic large cell lymphoma (NCT00866047). ClinicalTrials.gov Web site, Accessed February 23, 2012.
77. Advani, R., Fanale, M., Brice, P. et al. Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. 16th Congr Eur Hematol Assoc (EHA) (June 9-12, London) 2011, Abst 0369
78. Pro, B., Advani, R., Brice, P. et al. Durable remissions with brentuximab vedotin (SGN-035): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). 47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011, Abst 8032.
79. Gopal, A.K., Ramchandren, R., Berryman, R.B. et al. Brentuximab vedotin (SGN-35) treatment in relapsed CD30- positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series. Bone Marrow Transplant 2011, 46(Suppl. 1): Abst O267.
80. An SGN-35 trial for patients who have previously participated in an SGN-35 study (NCT00947856). ClinicalTrials.gov Web site, Accessed March 4, 2012.
81. Brentuximab vedotin (SGN-35) in transplant eligible patients with relapsed or refractory Hodgkin Lymphoma (NCT01508312). ClinicalTrials.gov Web site, Accessed March 4, 2012.
82. SGN-35 in CD30-positive lymphoproliferative disorders (ALCL), mycosis fungoides (MF), and extensive lymphomatoid papulosis (LyP) (NCT01352520). ClinicalTrials.gov Web site, Accessed March 4, 2012.
83. Brentuximab vedotin and combination chemotherapy in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (NCT01476410). ClinicalTrials.gov Web site, Accessed March 4, 2012.
84. Brentuximab vedotin before autologous stem cell transplant in treating patients with Hodgkin lymphoma (NCT01393717). ClinicalTrials.gov Web site, Accessed March 4, 2012.
85. Brentuximab plus AVD in limited-stage Hodgkin lymphoma (NCT01534078). ClinicalTrials.gov Web site, Accessed March 4, 2012.
86. A phase 3 study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma following stem cell transplant (The AETHERA Trial) (NCT01100502). ClinicalTrials.gov Web site, Accessed March 4, 2012.
87. Seattle Genetics pipeline. http://www.seagen.com/product-pipeline-sgn35. shtml. Accessed February 27, 2012.
88. Seattle Genetics products. http://www.seagen.com/product-adcetris.shtml Accessed February 27, 2012.